Cytosorbents Crp Company Leadership

CTSO Stock  USD 0.81  0.01  1.25%   
Cytosorbents Crp's insiders are aggressively buying. The analysis of insiders' sentiment of trading Cytosorbents Crp stock suggests that virtually all insiders are extremely bullish at this time. Cytosorbents Crp employs about 186 people. The company is managed by 20 executives with a total tenure of roughly 135 years, averaging almost 6.0 years of service per executive, having 9.3 employees per reported executive.
Phillip Chan  CEO
President CEO, Director
Al Kraus  Chairman
Chairman of the Board

Cytosorbents Crp's Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2023-12-13Alan D SobelAcquired 22557 @ 1.33View
2023-08-07Michael G BatorAcquired 2000 @ 3.17View
2023-08-04Michael G BatorAcquired 1000 @ 3.23View
2023-05-25Kathleen P BlochAcquired 3300 @ 2.85View
2023-05-10Kathleen P BlochAcquired 10000 @ 3.11View
Monitoring Cytosorbents Crp's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Cytosorbents Crp Management Team Effectiveness

The company has return on total asset (ROA) of (0.3248) % which means that it has lost $0.3248 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9721) %, meaning that it created substantial loss on money invested by shareholders. Cytosorbents Crp's management efficiency ratios could be used to measure how well Cytosorbents Crp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to grow to -0.75. At this time, Cytosorbents Crp's Total Assets are very stable compared to the past year. As of the 23rd of April 2024, Non Current Assets Total is likely to grow to about 28.9 M, while Total Current Assets are likely to drop about 17.6 M.
As of the 23rd of April 2024, Common Stock Shares Outstanding is likely to grow to about 46.9 M, though Net Loss is likely to grow to (28.1 M).

Cytosorbents Crp Workforce Comparison

Cytosorbents Crp is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 7,076. Cytosorbents Crp holds roughly 186 in number of employees claiming about 2.63% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.78) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.02.

Cytosorbents Crp Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytosorbents Crp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytosorbents Crp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cytosorbents Crp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cytosorbents Crp Notable Stakeholders

A Cytosorbents Crp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytosorbents Crp often face trade-offs trying to please all of them. Cytosorbents Crp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytosorbents Crp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Phillip ChanPresident CEO, DirectorProfile
Al KrausChairman of the BoardProfile
Vincent MSPresident COOProfile
Kathleen BlochCFOProfile
Vincent CapponiCOOProfile
Alan SobelDirectorProfile
Michael BatorDirectorProfile
James GuntonIndependent DirectorProfile
Edward JonesIndependent DirectorProfile
CPA CPACFO SecProfile
MS MSPres COOProfile
Christian MDExecutive MarketingProfile
FACC FESCChief OfficerProfile
Jodi HooverExecutiveProfile
Robert MDCoChairman ConsultantProfile
MS MBASenior DevelopmentProfile
Terri MBAVice CommunicationsProfile
Irina KulinetsSenior AffairsProfile
Eric MortensenChief Medical OfficerProfile
Robert BartlettChief Medical OfficerProfile

About Cytosorbents Crp Management Performance

The success or failure of an entity such as Cytosorbents Crp often depends on how effective the management is. Cytosorbents Crp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytosorbents management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytosorbents management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.58)(0.61)
Return On Capital Employed(0.79)(0.75)
Return On Assets(0.54)(0.56)
Return On Equity(1.22)(1.16)
The data published in Cytosorbents Crp's official financial statements usually reflect Cytosorbents Crp's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cytosorbents Crp. For example, before you start analyzing numbers published by Cytosorbents accountants, it's critical to develop an understanding of what Cytosorbents Crp's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Cytosorbents Crp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytosorbents Crp's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cytosorbents Crp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cytosorbents Crp. Please utilize our Beneish M Score to check the likelihood of Cytosorbents Crp's management manipulating its earnings.

Cytosorbents Crp Workforce Analysis

Traditionally, organizations such as Cytosorbents Crp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytosorbents Crp within its industry.

Cytosorbents Crp Manpower Efficiency

Return on Cytosorbents Crp Manpower

Revenue Per Employee195.4K
Revenue Per Executive1.8M
Net Loss Per Employee153.3K
Net Loss Per Executive1.4M
Working Capital Per Employee60K
Working Capital Per Executive557.8K
When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Cytosorbents Stock analysis

When running Cytosorbents Crp's price analysis, check to measure Cytosorbents Crp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Crp is operating at the current time. Most of Cytosorbents Crp's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Crp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytosorbents Crp's price. Additionally, you may evaluate how the addition of Cytosorbents Crp to your portfolios can decrease your overall portfolio volatility.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Cytosorbents Crp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.64)
Revenue Per Share
0.814
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.32)
Return On Equity
(0.97)
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.